Clearstead Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Clearstead Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-500	Closed	-$545	–	1375
2023 Q1	$545	Hold	500	–	–	﹤0.01%	1292
2022 Q4	$730	Hold	500	–	–	﹤0.01%	1197
2022 Q3	$1K	Hold	500	–	–	﹤0.01%	1120
2022 Q2	$1K	Hold	500	–	–	﹤0.01%	1150
2022 Q1	$1K	Hold	500	–	–	﹤0.01%	1259
2021 Q4	$2K	Hold	500	–	–	﹤0.01%	1089
2021 Q3	$3K	Hold	500	–	–	﹤0.01%	1068
2021 Q2	$2K	Hold	500	–	–	﹤0.01%	1010
2021 Q1	$3K	Buy	+500	New	+$2.86K	﹤0.01%	909

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Clearstead Advisors's ADAP Position: Q2 2023 in Review

Clearstead Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q2 2023, closing a stake of 500 shares — an estimated $545 sold.

Clearstead Advisors first reported a position in ADAP in Q1 2021 and held it in 9 quarters. The position peaked at $3K in Q3 2021. 89 funds tracked by Wall St. Rank hold ADAP as of Q2 2023.

Clearstead Advisors reported no remaining Adaptimmune Therapeutics position as of Q2 2023 after selling out during the quarter.
Clearstead Advisors sold 500 Adaptimmune Therapeutics shares in Q2 2023, an estimated $545.
Clearstead Advisors first reported a position in Adaptimmune Therapeutics in Q1 2021 and held it in 9 quarters.
Clearstead Advisors's Adaptimmune Therapeutics position peaked at $3K in Q3 2021.
89 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2023.

Based on Clearstead Advisors's 13F filing for Q2 2023, filed 7 Aug 2023.